Press Release

« Back

Nov 04, 2021

Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update

Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively  

On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care in the fourth quarter of 2021 

Company plans to initiate a Phase 3 program evaluating KarXT for the treatment of psychosis in elderly patients with Alzheimer’s disease in mid-2022  

$498.9 million in cash expected to fund operations, including multiple milestones, for at least 12 months following the potential New Drug Application (NDA) submission of KarXT in schizophrenia

BOSTON--(BUSINESS WIRE)--Nov. 4, 2021-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the third quarter of 2021 and provided a general business update.

“We continue to progress our late-stage clinical programs evaluating KarXT in schizophrenia, including the ongoing enrollment in our EMERGENT program, comprised of four Phase 3 trials, with topline data from the first trial expected in mid-2022, and the Phase 3 ARISE trial, which is on track to initiate by the end of the year,” said Steve Paul, M.D., chief executive officer, president and chairman. “This robust development program is a testament to our confidence in the novel mechanism of action of KarXT, as demonstrated by the compelling clinical data to date, and the promise it has to treat the multiple symptom domains of schizophrenia as both a monotherapy and an adjunctive therapy in adults who do not respond adequately to current standard of care.”

“We have also advanced our efforts in dementia-related psychosis, with an initial focus on developing KarXT for Alzheimer’s disease, the leading form of dementia in the U.S. Nearly half of those living with Alzheimer’s disease experience symptoms of psychosis and related behavioral disturbances, such as agitation and aggression, which can negatively impact and disrupt day-to-day functioning of patients and caregivers alike. There is a dire need for an effective therapy that can alleviate these disabling symptoms,” added Dr. Paul. “We look forward to building on the encouraging data seen in an earlier Phase 2 study of xanomeline in treating and preventing symptoms of psychosis in Alzheimer’s disease as we progress KarXT into late-stage clinical studies in mid-2022.”

Pipeline Updates
Karuna is advancing a pipeline of novel drug candidates for the treatment of various psychiatric and neurological conditions. The clinical pipeline is led by KarXT (xanomeline-trospium), an oral investigational antipsychotic with a novel mechanism of action mediated via muscarinic cholinergic receptors, which is currently being evaluated in late-stage clinical trials as a potential treatment for schizophrenia and Alzheimer’s disease psychosis.

  • KarXT for the treatment of psychosis in adults with schizophrenia. The EMERGENT program, the clinical program evaluating KarXT for the treatment of schizophrenia, is underway. The EMERGENT program includes the completed positive Phase 2 EMERGENT-1 trial and four ongoing Phase 3 trials, including:
    • EMERGENT-2: A five-week inpatient trial evaluating the efficacy and safety of KarXT compared to placebo in 246 adults with schizophrenia in the U.S.
      • Enrollment for this trial began in December 2020, with topline data expected mid-2022.
    • EMERGENT-3:A five-week inpatient trial evaluating the efficacy and safety of KarXT compared to placebo in 246 adults with schizophrenia in the U.S. and Ukraine.
      • Enrollment for this trial began in the second quarter of 2021, with topline data expected in the second half of 2022.
    • EMERGENT-4:A 52-week outpatient, open-label extension trial evaluating the long-term safety and tolerability of KarXT in 350 adults with schizophrenia who completed EMERGENT-2 or EMERGENT-3.
      • Enrollment for this trial began in the first quarter of 2021.
    • EMERGENT-5:A 52-week outpatient, open-label trial evaluating the long-term safety and tolerability of KarXT in 400 adults with schizophrenia in the U.S. in patients who were not enrolled in EMERGENT-2 or EMERGENT-3.
      • Enrollment for this trial began in the second quarter of 2021.
  • KarXT for the treatment of schizophrenia in adults who experience an inadequate response to current standard of care. The Phase 3 ARISE trial evaluating the safety and efficacy of KarXT compared to placebo as an adjunctive treatment for schizophrenia is on track to initiate in the fourth quarter of 2021.
  • KarXT for the treatment of psychosis in Alzheimer’s disease. The evaluation of KarXT for the treatment of dementia-related psychosis (DRP) will initially focus on psychosis in Alzheimer’s disease, the most common subtype of DRP. The initial focus on the Alzheimer’s disease dementia subtype reflects various strategic development, regulatory and commercial considerations, and the Company remains interested in exploring KarXT in other dementia subtypes in future development programs. Details of the Phase 3 Alzheimer’s disease psychosis program will be available in the first half of 2022 prior to the program’s initiation in mid-2022.
  • Discovery and early-stage pipeline. The Company continues to advance its earlier pipeline of muscarinic receptor targeted programs and novel formulations of KarXT, including a Phase 1 trial of an advanced formulation of KarXT expected to initiate in the fourth quarter of 2021, as well as its artificial intelligence-based target agnostic discovery program for treating psychiatric and neurological conditions.

Business Updates

  • COVID-19 update. The Company continues to monitor the impact of COVID-19 on operations and will provide relevant updates on its impact on activities as deemed appropriate.

Anticipated Upcoming Milestones

  • Initiation of the Phase 3 ARISE trial (4Q 2021)
  • Initiation of the Phase 3 program evaluating KarXT for the treatment of psychosis in Alzheimer’s disease (mid-2022)
  • Topline data from the Phase 3 EMERGENT-2 trial (mid-2022)
  • Topline data from the Phase 3 EMERGENT-3 trial (2H 2022)

Third Quarter 2021 Financial Results
The Company reported a net loss of $50.9 million for the third quarter of 2021, as compared to $18.8 million for the prior year comparable period. The increase in net loss for the quarter was due to higher research and development expenses related to the Company’s enrollment of the Phase 3 EMERGENT trials, NDA-supporting activities, start-up activities related to the Phase 3 ARISE trials, increased employee headcount across the organization and higher stock-based compensation expense.

Research and development expenses were $38.8 million for the third quarter of 2021, as compared to $12.6 million the prior year comparable period. The increase in research and development expenses for the quarter was primarily driven by expenses related to the Company’s enrollment of the Phase 3 EMERGENT trials, manufacturing in preparation for a potential NDA submission, start-up activities related to the Phase 3 ARISE trials, personnel-related costs due to the increase in employee headcount and higher stock-based compensation expense.

General and administrative expenses were $12.4 million for the third quarter of 2021, as compared to $6.9 million for the prior year comparable period. The increase in general and administrative expenses was primarily due to an increase in employee headcount and higher stock-based compensation expense as well as an increase in professional fees.

The Company ended the quarter with $498.9 million in cash, cash equivalents and available-for-sale investment securities compared to $322.3 million as of December 31, 2020. The increase was the result of the completion of the Company’s public offering in March 2021, partially offset by cash used in operations for the nine months ended September 30, 2021. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of September 30, 2021 will enable the Company to fund its operating expenses and capital expenditure requirements for at least 12 months following the potential NDA submission of KarXT for the treatment of psychosis in adults with schizophrenia.

About Karuna Therapeutics
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the timing of our ongoing and planned clinical trials and regulatory filings, our goals to develop and commercialize our product candidates, our liquidity and capital resources and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to obtain necessary funding, our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, risks relating to business interruptions resulting from the coronavirus (COVID-19) pandemic, and other risks set forth under the heading “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Karuna Therapeutics, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share data)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

38,775

 

 

$

12,585

 

 

$

83,108

 

 

$

27,824

 

General and administrative

 

 

12,393

 

 

 

6,944

 

 

 

32,554

 

 

 

19,585

 

Total operating expenses

 

 

51,168

 

 

 

19,529

 

 

 

115,662

 

 

 

47,409

 

Loss from operations

 

 

(51,168

)

 

 

(19,529

)

 

 

(115,662

)

 

 

(47,409

)

Other income (loss), net:

 

 

 

 

 

 

 

 

 

 

 

 

Impairment loss on right-of-use assets

 

 

 

 

 

 

 

 

(677

)

 

 

 

Interest income

 

 

114

 

 

 

688

 

 

 

363

 

 

 

2,864

 

Sublease income

 

 

122

 

 

 

 

 

 

131

 

 

 

 

Total other income (loss), net

 

 

236

 

 

 

688

 

 

 

(183

)

 

 

2,864

 

Net loss before income taxes

 

 

(50,932

)

 

 

(18,841

)

 

 

(115,845

)

 

 

(44,545

)

Income tax provision

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(50,932

)

 

$

(18,841

)

 

$

(115,845

)

 

$

(44,545

)

Net loss per share, basic and diluted

 

$

(1.72

)

 

$

(0.71

)

 

$

(4.00

)

 

$

(1.69

)

Weighted average common shares
outstanding used in computing net loss per
share, basic and diluted

 

 

29,572,289

 

 

 

26,663,968

 

 

 

28,953,654

 

 

 

26,298,969

 

Karuna Therapeutics, Inc.
Unaudited Consolidated Balance Sheet Data
(in thousands)

 

 

September 30, 2021

 

 

December 31, 2020

 

Cash, cash equivalents and investments

 

$

498,903

 

 

$

322,330

 

Working capital

 

 

513,663

 

 

 

337,746

 

Total assets

 

 

540,098

 

 

 

347,625

 

Total stockholders’ equity

 

$

518,328

 

 

$

338,931

 

 

Investors:
Alexis Smith
518-338-8990
asmith@karunatx.com

Source: Karuna Therapeutics, Inc.

Top